Key opinion leaders explore strategies for managing common side effects associated with metastatic castration-resistant prostate cancer (mCRPC) treatments, including androgen receptor-targeted therapies.
Gautam Jayram, MD
Advertisement
Articles by Gautam Jayram, MD
Key opinion leaders explore the role of androgen receptor-targeted therapy in mCRPC.
Key opinion leaders explore the expanding treament landscape for mCRPC.
Advertisement
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
3
Pearls & Perspectives: Expanding Options for Men With Erectile Dysfunction, With Tom Riester
4
RAD-IO: Durvalumab plus chemoradiotherapy is feasible in MIBC
5